Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Exicure, Inc. (NYSE American:XCUR), is developing nucleic acid-based therapeutics to treat rare, severe genetic diseases and cancer. XCUR will be presenting at this year's virtual Fall Investor Summit on November 16 th -18 th . The Fall Invest...
Exicure (XCUR): Q3 GAAP EPS of -$0.10 misses by $0.01.Revenue of $2.44M (+360.4% Y/Y) beats by $0.67M.Press Release For further details see: Exicure EPS misses by $0.01, beats on revenue
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter and nine months ended September 30, 2020 and provided an update on corporate progress. ...
- Confirmed overall response rate (ORR) of 21% in the Phase 1b dose-escalation stage across all doses, with 1 complete response and 3 partial responses - Confirmed ORR 33% at the highest and recommended Phase 2 dose - Durable and ongoing responses at the time of data a...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020. Date: Monday, O...
Exicure (XCUR) has closed $25M senior secured term loan with interest payments only for 24 months . The company has received $17.5M of proceeds, and an additional $7.5M can be drawn anytime between April 1, 2021 and September 30, 2021. "We believe this non-dilutive debt facility has...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust (MidCap), as agent, and Silicon Vall...
Exicure (NASDAQ: XCUR ) announces positive preliminary data from a Phase 1b clinical trial evaluating cavrotolimod, combined with Merck's (NYSE: MRK ) Keytruda (pembrolizumab), for the treatment of solid tumors. More news on: Exicure, Inc., Merck & Co., Inc., Healthcare stocks ...
Confirmed overall response rate (ORR) of 21% in the dose-escalation stage across all doses, confirmed ORR 33% at the highest and selected Phase 2 dose Target tumor shrinkage was observed in 37% of patients Preliminary data show activity in patients with melanoma, Merkel cell c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-3.60% Change Percent:
Exicure Inc. Company Name:
XCUR Stock Symbol:
OTCMKTS Market:
Exicure Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...